Arcturus Therapeutics Holdings Inc.ARCTEarnings & Financial Report
Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA (siRNA), messenger RNA (mRNA), gene editing RNA, DNA, antisense oligonucleotides, and microRNA.
ARCT Q4 FY2025 Key Financial Metrics
Revenue
$7.2M
Gross Profit
N/A
Operating Profit
N/A
Net Profit
N/A
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
-68.4%
Arcturus Therapeutics Holdings Inc. Q4 FY2025 Financial Summary
Arcturus Therapeutics Holdings Inc. reported revenue of $7.2M (down 68.4% YoY) for Q4 FY2025, with a net profit of N/A (up 3.1% YoY) (N/A margin).
Key Financial Metrics
| Total Revenue | $7.2M |
|---|---|
| Net Profit | N/A |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q4 FY2025 |
Arcturus Therapeutics Holdings Inc. Annual Revenue by Year
Arcturus Therapeutics Holdings Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $82.0M).
Arcturus Therapeutics Holdings Inc. Quarterly Revenue & Net Profit History
Arcturus Therapeutics Holdings Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $7.2M | -68.4% | N/A | N/A |
| Q3 FY2025 | $17.2M | -58.8% | $-13.4M | -78.4% |
| Q2 FY2025 | $28.3M | -43.2% | $-9.2M | -32.4% |
| Q1 FY2025 | $29.4M | -22.7% | $-14.1M | -47.9% |
| Q4 FY2024 | $22.8M | -26.2% | $-30.0M | -131.8% |
| Q3 FY2024 | $41.7M | -7.7% | $-6.9M | -16.6% |
| Q2 FY2024 | $49.9M | +374.0% | $-17.2M | -34.5% |
| Q1 FY2024 | $38.0M | -52.7% | $-26.8M | -70.5% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $38.0M | $49.9M | $41.7M | $22.8M | $29.4M | $28.3M | $17.2M | $7.2M |
| YoY Growth | -52.7% | 374.0% | -7.7% | -26.2% | -22.7% | -43.2% | -58.8% | -68.4% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $418.8M | $388.6M | $370.7M | $344.1M | $331.8M | $309.3M | $282.3M | $271.1M |
| Liabilities | $154.9M | $130.0M | $108.8M | $103.1M | $98.0M | $78.2M | $57.8M | $57.2M |
| Equity | $264.0M | $258.6M | $261.9M | $241.0M | $233.8M | $231.1M | $224.6M | $214.0M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-5.6M | $-30.1M | $-23.8M | $-284000 | $-35.1M | $-5.8M | $-17.2M | $-74.3M |